Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | BRAF | P15056 | 11/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91476 | 0.84 | MAPK1 (0.49) | ALDH1A1HRH4MAPK1NR3C1 | |
| SCHEMBL84377 | 0.79 | KDM4D (0.45) | ALDH1A1HRH4MAPK1 | |
| SCHEMBL84439 | 0.79 | HRH4 (0.54) | HRH4 | |
| SCHEMBL84101 | 0.78 | ACACB (0.50) | HRH4 | |
| SCHEMBL21918879 | 0.77 | MAPK1 (0.46) | ALDH1A1MAPK1 | |
| SCHEMBL84443 | 0.76 | HRH4 (0.44) | ALDH1A1HRH4BRAF | |
| SCHEMBL84098 | 0.76 | BRAF (0.46) | BRAF | |
| SCHEMBL84608 | 0.76 | ACACB (0.39) | HRH4BRAF | |
| SCHEMBL84422 | 0.74 | ACACB (0.39) | HRH4BRAF | |
| SCHEMBL84432 | 0.74 | ACACB (0.40) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | ALDH1A1 3257/4885HRH4 2437/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.